SCHEMBL17828918

SCHEMBL17828918

c1ccc(-n2c3ccccc3c3cc(-c4ccc5c6ccccc6n(-c6ccc(-c7nc(-n8c9ccccc9c9ccc(-c%10ccc%11c(c%10)c%10ccccc%10n%11-c%10ccccc%10)cc98)c8ccc9ccccc9c8n7)cc6)c5c4)ccc32)cc1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ATM Q13315 1/20 0.40
CYP1A1 P04798 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP1B1 Q16678 1/20 0.39
PTGER4 P35408 1/20 0.36
F2 P00734 1/20 0.34
F10 P00742 1/20 0.34
PRSS1 P07477 1/20 0.34
ABCG2 Q9UNQ0 3/20 0.33
PTGES O14684 1/20 0.32
MAT2A P31153 1/20 0.32
HDAC4 P56524 1/20 0.31
MAOA P21397 1/20 0.31
PIK3CD O00329 1/20 0.30
PIK3CA P42336 1/20 0.30
MTOR P42345 1/20 0.30
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17904226 1.00 L3MBTL1 (0.40) L3MBTL1KDM4EATMCYP1A1CYP1A2
SCHEMBL17828802 0.99 KDM4E (0.39) L3MBTL1KDM4EATMCYP1A1CYP1A2
SCHEMBL17829122 0.98 L3MBTL1 (0.42) L3MBTL1KDM4EATMCYP1A1CYP1A2
SCHEMBL17829136 0.97 L3MBTL1 (0.41) L3MBTL1KDM4EATMCYP1A1CYP1A2
SCHEMBL17828870 0.97 KDM4E (0.41) L3MBTL1KDM4EATMCYP1A1CYP1A2
SCHEMBL17828927 0.97 L3MBTL1 (0.43) L3MBTL1KDM4EATMCYP1A1CYP1A2
SCHEMBL17828928 0.95 L3MBTL1 (0.42) L3MBTL1KDM4EATMCYP1A1CYP1A2
SCHEMBL17828914 0.95 KDM4E (0.36) L3MBTL1KDM4EATMCYP1A1CYP1A2
SCHEMBL17828831 0.95 KDM4E (0.38) L3MBTL1KDM4EATMCYP1A1CYP1A2
SCHEMBL17828827 0.94 KDM4E (0.37) L3MBTL1KDM4EATMCYP1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9508939-B2 Compound and organic electroluminescent element produced using same IDEMITSU KOSAN CO., LTD. (JP) 2016-11-29 US disclosed
US-9508939-B2 Compound and organic electroluminescent element produced using same IDEMITSU KOSAN CO., LTD. (JP) 2016-11-29 US disclosed
US-20160172604-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT PRODUCED USING SAME IDEMITSU KOSAN CO., LTD. (JP) 2016-06-16 US disclosed
US-20160172604-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT PRODUCED USING SAME IDEMITSU KOSAN CO., LTD. (JP) 2016-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160172604-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT PRODUCED USING SAME L1CAM, LEF1, EML4 L3MBTL1 271/4885KDM4E 2236/4885ATM 2921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.